https://www.viridiantherapeutics.com/document/ 2026-07-13T17:29:28+00:00 https://www.viridiantherapeutics.com/document/thrive-and-thrive-2-phase-3-trials-of-vrdn-001-in-thyroid-eye-disease-next-generation-insulin-like-growth-factor-1-receptor-blockade/ 2025-03-18T14:07:06+00:00 https://www.viridiantherapeutics.com/document/clinical-activity-and-safety-of-vrdn-001-a-full-antagonist-antibody-to-insulin-like-growth-factor-1-receptor-in-active-and-chronic-thyroid-eye-disease/ 2025-03-18T14:06:31+00:00 https://www.viridiantherapeutics.com/document/vrdn-003-next-generation-full-antagonist-monoclonal-antibody-to-igf-1r-two-randomized-placebo-controlled-clinical-studies-in-patients-with-ted-reveal-1-and-reveal-2/ 2025-03-17T15:43:23+00:00 https://www.viridiantherapeutics.com/document/vrdn-003-a-novel-half-life-extended-igf-1-receptor-antibody-for-thyroid-eye-disease-ted-preclinical-pharmacokinetics/ 2025-03-15T16:42:15+00:00 https://www.viridiantherapeutics.com/document/vrdn-003-a-full-antagonist-antibody-to-igf-1r-for-thyroid-eye-disease-ted-phase-1-results-in-healthy-volunteers-show-potential-for-subcutaneous-administration/ 2025-03-15T16:41:18+00:00 https://www.viridiantherapeutics.com/document/vrdn-002-a-second-generation-insulin-like-growth-factor-1-receptor-igf-1r-antibody-for-ted-preclinical-pk-profile-and-clinical-promise/ 2025-03-15T16:40:44+00:00 https://www.viridiantherapeutics.com/document/vrdn-002-a-novel-antagonist-antibody-to-igf-1-receptor-for-thyroid-eye-disease-ted-results-of-a-phase-1-trial/ 2025-03-15T16:40:12+00:00 https://www.viridiantherapeutics.com/document/vrdn-002-a-next-generation-half-life-extended-antagonist-antibody-to-igf-1-receptor-for-thyroid-eye-disease-ted-safety-and-pharmacokinetic-pharmacodynamic-pk-pd-results-in-healthy-volunteers/ 2025-03-15T16:39:36+00:00 https://www.viridiantherapeutics.com/document/vrdn-001-a-potent-and-selective-insulin-like-growth-factor-1-receptor-igf-1r-antagonist-antibody-for-thyroid-eye-disease-ted-phase-1-safety-and-pharmacodynamic-results-in-healthy-volunteers/ 2025-03-15T16:39:06+00:00 https://www.viridiantherapeutics.com/document/vrdn-001-a-full-antagonist-antibody-to-the-insulin-like-growth-factor-1-receptor-igf-1r-for-thyroid-eye-disease-ted-phase-1-2-proof-of-concept-in-patients-with-ted/ 2025-03-15T16:34:57+00:00 https://www.viridiantherapeutics.com/document/vrdn-001-a-full-antagonist-antibody-to-the-insulin-like-growth-factor-1-receptor-igf-1r-for-thyroid-eye-disease-ted-binds-to-a-distinct-epitope-from-teprotumumab/ 2025-03-15T16:20:27+00:00 https://www.viridiantherapeutics.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1r-proof-of-concept-results-in-chronic-ted/ 2025-03-15T16:19:59+00:00 https://www.viridiantherapeutics.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1r-in-development-for-thyroid-eye-disease-ted-binds-to-a-distinct-epitope-from-teprotumumab/ 2025-03-15T16:15:03+00:00 https://www.viridiantherapeutics.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-vitro-pharmacology-and-phase-1-2-results-in-patients-with-thyroid-eye-disease-ted/ 2025-03-15T16:14:33+00:00 https://www.viridiantherapeutics.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-development-for-thyroid-eye-disease-ted-pharmacodynamic-responses-in-healthy-volunteers-and-patients-with-active-ted/ 2025-03-15T16:13:43+00:00 https://www.viridiantherapeutics.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-development-for-thyroid-eye-disease-ted-interim-phase-1-2-pharmacodynamic-results/ 2025-03-15T16:13:17+00:00 https://www.viridiantherapeutics.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-for-thyroid-eye-disease-ted-phase-1-2-clinical-study-in-patients/ 2025-03-15T16:12:57+00:00 https://www.viridiantherapeutics.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-for-thyroid-eye-disease-ted-in-vitro-pharmacology-and-clinical-phase-1-2-results/ 2025-03-15T16:12:30+00:00 https://www.viridiantherapeutics.com/document/vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-development-for-thyroid-eye-disease-ted-binds-to-a-distinct-epitope-from-teprotumumab/ 2025-03-15T16:11:55+00:00 https://www.viridiantherapeutics.com/document/veligrotug-vrdn-001-a-targeted-ted-therapy-disease-modifying-effects-on-proptosis-and-muscle-fat-volume-by-mri-ct-in-a-proof-of-concept-study-in-ted/ 2025-03-15T16:11:32+00:00 https://www.viridiantherapeutics.com/document/two-randomized-placebo-controlled-clinical-studies-planned-to-assess-subcutaneous-administration-of-vrdn-003-a-next-generation-full-antagonist-antibody-to-igf-1r-in-patients-with-thyroid-eye-disease/ 2025-03-15T16:10:56+00:00 https://www.viridiantherapeutics.com/document/thrive-phase-3-trial-of-vrdn-001-a-full-antagonist-antibody-to-the-igf-1-receptor-for-thyroid-eye-disease-ted/ 2025-03-15T16:10:22+00:00 https://www.viridiantherapeutics.com/document/subcutaneous-vrdn-003-vs-veligrotug-vrdn-001-full-antagonist-monoclonal-antibodies-to-igf-1r-for-thyroid-eye-disease-ted-phase-1-safety-pk-pd-studies-in-healthy-volunteers/ 2025-03-15T15:21:54+00:00 https://www.viridiantherapeutics.com/document/preclinical-pharmacokinetics-of-vrdn-003-a-next-generation-half-life-extended-antibody-to-the-igf-1-receptor-for-thyroid-eye-disease/ 2025-03-15T15:19:52+00:00 https://www.viridiantherapeutics.com/document/preclinical-pharmacokinetics-and-clinical-exposure-prediction-for-vrdn-003-a-next-generation-half-life-extended-antibody-to-the-igf-1-receptor-for-thyroid-eye-disease-ted/ 2025-03-15T15:19:16+00:00 https://www.viridiantherapeutics.com/document/preclinical-pharmacokinetics-and-bioavailability-of-vrdn-002-a-next-generation-half-life-extended-antagonist-antibody-to-the-igf-1-receptor-for-thyroid-eye-disease-ted/ 2025-03-15T15:18:48+00:00 https://www.viridiantherapeutics.com/document/phase-1-2-trial-of-vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-patients-with-thyroid-eye-disease-ted/ 2025-03-15T15:17:06+00:00 https://www.viridiantherapeutics.com/document/phase-1-results-in-healthy-volunteers-show-potential-for-subcutaneous-administration-of-vrdn-003-a-half-life-extended-full-antagonist-antibody-to-igf-1r-for-thyroid-eye-disease-ted/ 2025-03-15T15:16:33+00:00 https://www.viridiantherapeutics.com/document/pharmacodynamic-responses-to-vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-development-for-thyroid-eye-disease-ted-in-healthy-volunteers-and-patients-with-active-ted/ 2025-03-15T15:15:55+00:00 https://www.viridiantherapeutics.com/document/mri-ct-analysis-shows-potential-for-disease-modifying-effects-of-vrdn-001-a-targeted-ted-therapy-reduced-proptosis-and-muscle-fat-volume-in-a-proof-of-concept-study-in-active-ted/ 2025-03-15T15:15:11+00:00 https://www.viridiantherapeutics.com/document/in-vitro-pharmacology-and-phase-1-2-results-of-vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-thyroid-eye-disease-ted/ 2025-03-15T14:58:45+00:00 https://www.viridiantherapeutics.com/document/in-vitro-pharmacology-and-phase-1-2-results-of-vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-for-thyroid-eye-disease-ted/ 2025-03-15T14:58:08+00:00 https://www.viridiantherapeutics.com/document/durability-of-treatment-response-with-vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-patients-with-thyroid-eye-disease-ted-phase-1-2-clinical-study/ 2025-03-15T14:57:36+00:00 https://www.viridiantherapeutics.com/document/durability-of-treatment-response-with-vrdn-001-a-full-antagonist-antibody-to-igf-1-receptor-in-patients-with-thyroid-eye-disease-ted-phase-1-2-clinical-study-2/ 2025-03-15T14:56:57+00:00 https://www.viridiantherapeutics.com/document/design-and-preclinical-characterization-of-vrdn-003-a-next-generation-half-life-extended-antibody-to-igf-1r-in-development-for-thyroid-eye-disease-ted/ 2025-03-15T14:55:52+00:00 https://www.viridiantherapeutics.com/document/clinical-activity-and-safety-of-vrdn-001-a-full-antagonist-antibody-to-insulin-like-growth-factor-1-receptor-in-active-and-chronic-thyroid-eye-disease-2/ 2025-03-15T14:54:55+00:00 https://www.viridiantherapeutics.com/document/characterization-of-vrdn-001-a-high-affinity-and-potent-anti-igf-1r-inhibitory-antibody-for-the-treatment-of-thyroid-eye-disease/ 2025-03-15T14:54:33+00:00 https://www.viridiantherapeutics.com/document/antagonist-properties-of-vrdn-003-a-next-generation-half-life-extended-antibody-to-igf-1-receptor-for-thyroid-eye-disease-ted/ 2025-03-15T14:54:10+00:00 https://www.viridiantherapeutics.com/document/vrdn-003-a-full-antagonist-antibody-to-the-igf-1-receptor-for-thyroid-eye-disease-ted-safety-and-pharmacokinetic-results-of-subcutaneous-administration-in-healthy-volunteers/ 2025-02-21T00:01:32+00:00 https://www.viridiantherapeutics.com/document/inhibition-of-igf-1-receptor-signaling-and-ocular-fibroblast-cell-growth-by-vrdn-001-vs-teprotumumab/ 2025-02-20T23:59:18+00:00 https://www.viridiantherapeutics.com/document/vrdn-001-vs-teprotumumab-inhibition-of-igf-1-receptor-signaling-and-ocular-fibroblast-cell-growth/ 2025-02-20T23:59:02+00:00 https://www.viridiantherapeutics.com/document/thrive-and-thrive-2-phase-3-trials-of-vrdn-001-in-thyroid-eye-disease-ted-next-generation-insulin-like-growth-factor-1-receptor-blockade/ 2025-02-20T23:58:45+00:00 https://www.viridiantherapeutics.com/document/pharmacokinetic-and-safety-results-of-vrdn-003-a-full-antagonist-antibody-to-the-igf-1-receptor-for-thyroid-eye-disease-in-healthy-volunteers-potential-for-subcutaneous-administration/ 2025-02-20T23:58:30+00:00